Change over period: —
NSE · MANKIND
MANKIND
-1.6% from the 52-week high · +36.2% above the low
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. The company is headquartered in New Delhi, Delhi and currently employs 18,468 full-time employees. The company went IPO on 2023-05-09. The firm is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.
The short version. MANKIND reported revenue of ₹4,338 crore for Sep 2026, up 17.3% from a year earlier. Net profit was ₹711 crore (up 38.9% year on year). Return on equity was 11.7% in Mar 2026. Promoter holding was 72.62% in Sep 2026, down 0.09 points over 8 quarters.
1 · The price
How has the stock traded?
MANKIND trades 1.6% below its 52-week high and 36.2% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹4,338 cr.
Sep 2026 net profit of ₹711 cr.
2.6 pts higher than a year earlier.
Revenue compounded at 18.1% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4338 | 4031 | 3443 | 3567 | 3697 | 3570 | 3079 | 3230 |
| Net profit | 711 | 574 | 554 | 409 | 512 | 438 | 421 | 380 |
| Net margin % | 16.4 | 14.2 | 16.1 | 11.5 | 13.8 | 12.3 | 13.7 | 11.8 |
| EPS (₹) | 17.23 | 13.9 | 13.43 | 9.9 | 12.39 | 10.62 | 10.2 | 9.22 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | 14278 | 12207 | 10335 | 8749 |
| Net profit | 1913 | 1991 | 1913 | 1282 |
| Net margin % | 13.4 | 16.3 | 18.5 | 14.7 |
| EPS (₹) | 46.34 | 48.26 | 47.75 | 32.0 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 11.7% in Mar 2026; debt to equity is 0.39.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 11.7 | 13.9 | 20.4 | 17.2 |
| Return on capital % | 13.7 | 13.3 | 24.6 | 21.7 |
| EBITDA margin % | 26.3 | 27.9 | 26.5 | 22.9 |
| Net margin % | 13.1 | 15.6 | 18.0 | 14.4 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 18.1% | — |
| Profit CAGR | 14.3% | — |
4 · The owners
Who holds it, and are they adding?
Down 0.09 pts over 8 quarters.
Down 3.97 pts over 8 quarters.
Up 4.5 pts over 8 quarters.
+61 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.71 | 72.7 | 72.68 | 72.67 | 72.66 | 72.66 | 72.63 | 72.62 | -0.09 |
| FII | 13.34 | 12.92 | 13.07 | 12.84 | 11.34 | 10.24 | 9.45 | 9.37 | -3.97 |
| DII | 11.06 | 11.48 | 11.5 | 11.92 | 13.25 | 14.46 | 15.39 | 15.56 | +4.5 |
| Public | 2.9 | 2.9 | 2.75 | 2.57 | 2.75 | 2.64 | 2.53 | 2.45 | -0.45 |
Mutual fund holdings · Oct 2026
244 schemes hold this stock
183 the month before.
- ICICI Prudential Healthcare Fund4.5% of NAV
- EDELWEISS FOCUSED FUND4.47% of NAV
- NIPPON INDIA PHARMA FUND4.4% of NAV
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND4.26% of NAV
- Motilal Oswal Nifty MidSmall Healthcare Index Fund4.25% of NAV
- PGIM INDIA HEALTHCARE FUND3.95% of NAV
- Motilal Oswal Innovation Opportunities Fund3.88% of NAV
- ITI Pharma and Healthcare Fund3.75% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for MANKIND are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about MANKIND
What is the MANKIND share price?
MANKIND (MANKIND) last closed at ₹2,629.00, up 0.15% on the day. Its 52-week range is ₹1,927.40 to ₹2,668.30.
What is the market cap of MANKIND?
MANKIND has a market capitalisation of about ₹108,424 crore. Its price-to-earnings ratio is 48.6.
How are MANKIND's latest results?
MANKIND reported revenue of ₹4,338 crore for Sep 2026, up 17.3% from a year earlier. Net profit was ₹711 crore (up 38.9% year on year). Return on equity was 11.7% in Mar 2026. Promoter holding was 72.62% in Sep 2026, down 0.09 points over 8 quarters.
Who owns MANKIND?
As of Sep 2026, shareholding was: Promoter 72.62%, FII 9.37%, DII 15.56%, Public 2.45%.
How many mutual funds hold MANKIND?
244 mutual fund schemes held MANKIND in October 2026. That compares with 183 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 08 Aug 2025 · Interim Dividend - Rs. 1
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.